223 related articles for article (PubMed ID: 28922087)
21. Cardiovascular Disease Risk in a Large, Population-Based Cohort of Breast Cancer Survivors.
Boekel NB; Schaapveld M; Gietema JA; Russell NS; Poortmans P; Theuws JC; Schinagl DA; Rietveld DH; Versteegh MI; Visser O; Rutgers EJ; Aleman BM; van Leeuwen FE
Int J Radiat Oncol Biol Phys; 2016 Apr; 94(5):1061-72. PubMed ID: 27026313
[TBL] [Abstract][Full Text] [Related]
22. Long-Term Cardiovascular Outcomes in Systemic Lupus Erythematosus.
Yafasova A; Fosbøl EL; Schou M; Baslund B; Faurschou M; Docherty KF; Jhund PS; McMurray JJV; Sun G; Kristensen SL; Torp-Pedersen C; Køber L; Butt JH
J Am Coll Cardiol; 2021 Apr; 77(14):1717-1727. PubMed ID: 33832598
[TBL] [Abstract][Full Text] [Related]
23. Low incidence of cardiotoxicity in patients with non-Hodgkin lymphoma receiving EPOCH after prior anthracycline exposure.
Buege MJ; Drill E; Horwitz SM; LeVoir A; Pak T; Peterson TJ; Dao PH; Matasar MJ
Eur J Haematol; 2023 Jul; 111(1):96-102. PubMed ID: 36971022
[TBL] [Abstract][Full Text] [Related]
24. Utilization of Cardiac Surveillance Tests in Survivors of Breast Cancer and Lymphoma After Anthracycline-Based Chemotherapy.
Ruddy KJ; Sangaralingham LR; Van Houten H; Nowsheen S; Sandhu N; Moslehi J; Neuman H; Jemal A; Haddad TC; Blaes AH; Villarraga HR; Thompson C; Shah ND; Herrmann J
Circ Cardiovasc Qual Outcomes; 2020 Mar; 13(3):e005984. PubMed ID: 32106704
[TBL] [Abstract][Full Text] [Related]
25. Long-term risk of cardiovascular disease after treatment for aggressive non-Hodgkin lymphoma.
Moser EC; Noordijk EM; van Leeuwen FE; le Cessie S; Baars JW; Thomas J; Carde P; Meerwaldt JH; van Glabbeke M; Kluin-Nelemans HC
Blood; 2006 Apr; 107(7):2912-9. PubMed ID: 16339404
[TBL] [Abstract][Full Text] [Related]
26. Cardiovascular mortality trends in non-Hodgkin's lymphoma: a population-based cohort study.
Kamel MG; El-Qushayri AE; Thach TQ; Huy NT
Expert Rev Anticancer Ther; 2018 Jan; 18(1):91-100. PubMed ID: 29192533
[TBL] [Abstract][Full Text] [Related]
27. Risk Factors for Melanoma Among Survivors of Non-Hodgkin Lymphoma.
Lam CJ; Curtis RE; Dores GM; Engels EA; Caporaso NE; Polliack A; Warren JL; Young HA; Levine PH; Elmi AF; Fraumeni JF; Tucker MA; Morton LM
J Clin Oncol; 2015 Oct; 33(28):3096-104. PubMed ID: 26240221
[TBL] [Abstract][Full Text] [Related]
28. Long-term risk of congestive heart failure in younger breast cancer survivors: A nationwide study by the SMARTSHIP group.
Lee J; Hur H; Lee JW; Youn HJ; Han K; Kim NW; Jung SY; Kim Z; Kim KS; Lee MH; Han SH; Jung SH; Chung IY
Cancer; 2020 Jan; 126(1):181-188. PubMed ID: 31454422
[TBL] [Abstract][Full Text] [Related]
29. Cardiovascular Manifestations of Systemic Sclerosis: A Danish Nationwide Cohort Study.
Butt SA; Jeppesen JL; Torp-Pedersen C; Sam F; Gislason GH; Jacobsen S; Andersson C
J Am Heart Assoc; 2019 Sep; 8(17):e013405. PubMed ID: 31446827
[TBL] [Abstract][Full Text] [Related]
30. Electrocardiographic PR Interval Duration and Cardiovascular Risk: Results From the Copenhagen ECG Study.
Rasmussen PV; Nielsen JB; Skov MW; Pietersen A; Graff C; Lind B; Struijk JJ; Olesen MS; Haunsø S; Køber L; Svendsen JH; Holst AG
Can J Cardiol; 2017 May; 33(5):674-681. PubMed ID: 28449838
[TBL] [Abstract][Full Text] [Related]
31. Development and Validation of Risk Prediction Models for Coronary Heart Disease and Heart Failure After Treatment for Hodgkin Lymphoma.
de Vries S; Haaksma ML; Jóźwiak K; Schaapveld M; Hodgson DC; Lugtenburg PJ; Krol ADG; Petersen EJ; van Spronsen DJ; Ahmed S; Hauptmann M; Aleman BMP; van Leeuwen FE
J Clin Oncol; 2023 Jan; 41(1):86-95. PubMed ID: 35947813
[TBL] [Abstract][Full Text] [Related]
32. Age-Related Disease Risks in Younger versus Older B-Cell Non-Hodgkin's Lymphoma Survivors.
Ocier K; Abdelaziz S; Kim S; Rowe K; Snyder J; Deshmukh VG; Newman M; Fraser A; Smith KR; Porucznik CA; Shoaf K; Stanford JB; Lee CJ; Hashibe M
Cancer Epidemiol Biomarkers Prev; 2021 Dec; 30(12):2268-2277. PubMed ID: 34732401
[TBL] [Abstract][Full Text] [Related]
33. Employment status at time of first hospitalization for heart failure is associated with a higher risk of death and rehospitalization for heart failure.
Rørth R; Fosbøl EL; Mogensen UM; Kragholm K; Numé AK; Gislason GH; Jhund PS; Petrie MC; McMurray JJV; Torp-Pedersen C; Køber L; Kristensen SL
Eur J Heart Fail; 2018 Feb; 20(2):240-247. PubMed ID: 29148231
[TBL] [Abstract][Full Text] [Related]
34. Statin use and survival in 16 098 patients with non-Hodgkin lymphoma or chronic lymphocytic leukaemia treated in the rituximab era.
Brånvall E; Ekberg S; Eloranta S; Wästerlid T; Birmann BM; Smedby KE
Br J Haematol; 2021 Nov; 195(4):552-560. PubMed ID: 34331461
[TBL] [Abstract][Full Text] [Related]
35. The Temporal Risk of Heart Failure Associated With Adjuvant Trastuzumab in Breast Cancer Patients: A Population Study.
Goldhar HA; Yan AT; Ko DT; Earle CC; Tomlinson GA; Trudeau ME; Krahn MD; Krzyzanowska MK; Pal RS; Brezden-Masley C; Gavura S; Lien K; Chan KK
J Natl Cancer Inst; 2016 Jan; 108(1):. PubMed ID: 26476433
[TBL] [Abstract][Full Text] [Related]
36. High serum erythropoietin levels are related to heart failure development in subjects from the general population with albuminuria: data from PREVEND.
Grote Beverborg N; van der Wal HH; Klip IT; Voors AA; de Boer RA; van Gilst WH; van Veldhuisen DJ; Gansevoort RT; Hillege HL; van der Harst P; Bakker SJ; van der Meer P
Eur J Heart Fail; 2016 Jul; 18(7):814-21. PubMed ID: 26781914
[TBL] [Abstract][Full Text] [Related]
37. Heart failure after treatment for breast cancer.
Boekel NB; Duane FK; Jacobse JN; Hauptmann M; Schaapveld M; Sonke GS; Gietema JA; Hooning MJ; Seynaeve CM; Maas AHEM; Darby SC; Aleman BMP; Taylor CW; van Leeuwen FE
Eur J Heart Fail; 2020 Feb; 22(2):366-374. PubMed ID: 31721395
[TBL] [Abstract][Full Text] [Related]
38. Long-term risk of cardiovascular disease in 10-year survivors of breast cancer.
Hooning MJ; Botma A; Aleman BM; Baaijens MH; Bartelink H; Klijn JG; Taylor CW; van Leeuwen FE
J Natl Cancer Inst; 2007 Mar; 99(5):365-75. PubMed ID: 17341728
[TBL] [Abstract][Full Text] [Related]
39. Adolescent weight and height are predictors of specific non-Hodgkin lymphoma subtypes among a cohort of 2,352,988 individuals aged 16 to 19 years.
Leiba M; Leiba A; Keinan-Boker L; Avigdor A; Derazne E; Levine H; Kark JD
Cancer; 2016 Apr; 122(7):1068-77. PubMed ID: 26900677
[TBL] [Abstract][Full Text] [Related]
40. Prevalence of cardiovascular risk factors in long-term survivors of childhood cancer: 16 years follow up from a prospective registry.
Felicetti F; D'Ascenzo F; Moretti C; Corrias A; Omedè P; Marra WG; Arvat E; Fagioli F; Brignardello E; Gaita F
Eur J Prev Cardiol; 2015 Jun; 22(6):762-70. PubMed ID: 24691151
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
